Innovators in Cancer Immunology: Colorectal Cancer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Colorectal Cancer

June 12, 2017

Innovators in Cancer Immunology: Colorectal Cancer


Jerome Galon, PhD
Director, Laboratory for Integrated Cancer Immunology
INSERM, Paris, France

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Jerome Galon’s laboratory aims to understand tumor progression and immune reaction against cancer by using integrative biology and bioinformatics to improve the therapeutic management of cancer patients. Dr. Galon and his associates hypothesize that integrative biology approaches will provide a better knowledge of the local interplay between immune components and tumor cells. Dr. Galon is known for discovering and developing the ‘Immunoscore’ for prognostic assessment of colorectal cancer. This was the first clear demonstration of the power of automation and cancer-immunology to stratify patients according to immune status and the likelihood of progression. He is now using Phenoptics to go beyond Immunoscore to explore higher multliplexed biomarkers to reveal deeper details about how cancer evades the immune system. Dr. Galen’s expectation is that the richer detail afforded by Phenoptics will lead to new treatable targets and better predictive tests for checkpoint inhibitors in colorectal cancer treatment.

Read More Stories Like This One

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the A...

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...